Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064495 | 1.00 | RIPK1 (0.44) | RIPK1TSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL25284940 | 0.96 | NR1H2 (0.42) | RIPK1TSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL25284679 | 0.84 | NR1H2 (0.48) | HSP90AA1NR1H2 | |
| SCHEMBL20170496 | 0.84 | HSP90AA1 (0.56) | RIPK1TSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL29747255 | 0.83 | RIPK1 (0.46) | RIPK1TSHRMEN1KMT2ALMNA | |
| SCHEMBL29747858 | 0.83 | NR1H2 (0.41) | TSHRALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL23579324 | 0.83 | RIPK1 (0.47) | RIPK1TSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL29748129 | 0.83 | RIPK1 (0.47) | RIPK1TSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL22165572 | 0.83 | RIPK1 (0.47) | RIPK1TSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL29747992 | 0.83 | MEN1 (0.48) | RIPK1TSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| CN-116217566-B | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| EP-4522169-A1 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | BeiGene Switzerland GmbH (CH) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119584963-A | Methods of treating multiple myeloma using BCL-2 inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119546615-A | Sonrotoclax intermediates and process for their preparation | 百济神州(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119301124-A | Ketal protected intermediates for Sonrotoclax and methods of making the same | 百济神州(苏州)生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-114478520-B | Bcl-2 protein apoptosis inducer and application thereof | 杭州和正医药有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-114929689-B | Bcl-2 inhibitors | 百济神州有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-117835974-A | Methods of treating B cell malignancies using BCL-2 inhibitors | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023218410-A1 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | BEIGENE SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | WO | disclosed |
| CN-116217566-A | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-114929689-A | Bcl-2 inhibitors | 百济神州有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022140224-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114478520-A | Bcl-2 protein apoptosis inducer and application thereof | 杭州和正医药有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | RIPK1 1579/4885TSHR 1810/4885HSP90AA1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.